In order to optimise the monitoring of potentially exposed workers, it is desirable to determine specific values of absorption for the compounds handled. This study derives specific values of absorption rates for different chemical forms of plutonium from in vitro and animal (monkeys, dogs, mice, rats) experiments, and from human contamination cases. Different published experimental data have been reinterpreted here to derive values for the absorption parameters, f r , s r and s s , used in the human respiratory tract model currently adopted by the International Commission on Radiological Protection (ICRP). The consequences of the use of these values were investigated by calculating related committed effective doses per unit intake. Average and median estimates were calculated for f r , s r , and s s for each plutonium compound, that can be used as default values for specific chemical forms instead of the current reference types. Nevertheless, it was shown that the use of the current ICRP reference absorption types provides reasonable approximations. Moreover, this work provides estimates of the variability in pulmonary absorption and, therefore, facilitates analyses of the uncertainties associated with assessments, either from bioassay measurements or from prospective calculations, of intake and dose.
Introduction
Plutonium (Pu) compounds are widely used as fuel in the nuclear power industry, for thermoelectric power sources of satellites and for military applications. Pu is also present in the spent fuel of nuclear reactors. Workers may be exposed to various chemical forms and isotopic compositions of Pu. Since the first use of Pu in the 1940s, the protection of workers and monitoring of exposure have been important issues due to the high radiotoxicity of this element. Biokinetic models have been developed by the International Commission on Radiological Protection (ICRP) to support the evaluation of dose resulting from internal contamination (ICRP 1997) . As inhalation of an aerosol is the most likely route of intake for workers, a key parameter of the related dose assessment is the solubility of Pu deposited in the lungs. Through the pulmonary absorption kinetics, it determines the fraction of the activity that is transferred from the lung to the blood and then to the systemic organs/tissues (primarily skeleton and liver) and, ultimately, to excretion.
The human respiratory tract model (HRTM) adopted by the ICRP (1994a) describes the deposition of an inhaled radionuclide in the respiratory tract, its clearance and the local dosimetry. The clearance is due to the mucociliary transport of the deposited particles to the alimentary tract in competition with transport to the regional lymph nodes and with absorption into blood. Absorption is a two-stage process: dissociation of material that can be absorbed into body fluids (dissolution); and absorption into body fluids of soluble material and of material dissociated from particles (uptake). Dissolution may be modelled by three parameters: a fraction f r of the activity is rapidly absorbed at a rate s r , the remaining fraction (1 − f r ) is absorbed at a slower rate s s . The ICRP recommends default values of these parameters for reference types of absorption: for Type F (fast), there is rapid absorption of the radionuclide with a half-time of about 10 min ( f r = 1, s r = 100 d −1 ); for Type M (moderate), 10% of the activity is absorbed with a half-time of 10 min and 90% with a half-time of 140 d ( f r = 0.1, s r = 100 d −1 and s s = 0.005 d −1 ); for Type S (slow), 0.1% is absorbed with a half-time of 10 min and 99.9% with a half-time of 7000 d ( f r = 0.001, s r = 100 d −1 , s s = 0.0001 d −1 ) (ICRP 1994a). In the absence of more specific information, one of the reference types can be chosen according to the chemical form of the radionuclide. For example, insoluble oxides of Pu are commonly modelled by Type S (ICRP 1994b) .
However, the choice of absorption type can dramatically influence the estimation of the dose from a given inhaled activity. For example, assuming an activity median aerodynamic diameter (AMAD) of 5 µm, the committed effective dose per unit intake (DPUI) varies from 8.4 × 10 −6 Sv Bq −1 for a 239 Pu Type S to 3.3 × 10 −5 Sv Bq −1 for a Type M and to 1.4 × 10 −4 Sv Bq −1 for a Type F. The absorption of an actual compound is usually intermediate between the reference types. Besides, the knowledge of a compound absorption influences the accuracy of the estimation of the dose from a given exposure as well as the definition of the monitoring programme. For instance, should the monitoring be carried out using urine or faeces measurement? Therefore, it is desirable to determine specific values of absorption for handled Pu compounds in order to optimise the monitoring of potentially exposed workers and to improve the evaluation of doses. Consistently, the ICRP recommends the use of specific values of the absorption parameters if they are known (ICRP 2002) and proposes, when no more precise information is available, reference values (Type F, M, S) (ICRP 1994a) and criteria to assign materials to Types F, M, S considering experimental data (ICRP 1995) .
This work intends to derive specific values of f r , s r and s s for different chemical forms of Pu from the literature. The consequences of the use of these values were investigated by calculating the related DPUI. Correlations between f r , s r and s s were studied as well.
Materials and methods
Information related to the pulmonary absorption of Pu was obtained from published in vitro and animal (monkeys, dogs, mice, rats) experiments, and human contamination cases. The McClellan ( literature review was as exhaustive as possible in considering original articles referenced by the ICRP (1995), the OMINEX report and the RBDATA-EULEP database (Bailey et al 2004) . In order to derive values of absorption parameters for the HRTM from the published experimental data, biokinetic models were adapted to the species for the deposition of the plutonium in the respiratory tract, its clearance and its systemic behaviour. They are used to estimate the excreted and retained activities in the different organs and to compare them with the experimental data. The fits of the model predictions to the data were performed with the software Simulation Analysis And Modeling (SAAM) II (SAAM Institute, University of Washington, USA, Barrett et al 1998) by varying the absorption parameters. The deposition in the compartments of the HRTM was calculated with the software LUng Dose Evaluation Program (LUDEP, Health Protection Agency, UK, Birchall et al 1991) .
Furthermore, in the respiratory tract model, the particle transport and the absorption into blood are assumed to be independent, the particle transport is assumed to be the same for all materials in the same species and the absorption into blood is assumed to be uniform in the entire respiratory tract (ICRP 1994a) . The decay of Pu in the body was neglected because of the long half-lives of 238 Pu (87.7 y) and of 239 Pu (2.41 × 10 +4 y) compared with the duration of the experiments.
In vitro studies
The in vitro experimental protocol consists of enclosing a sample within a sandwich of two filter papers and then in suspending it in a solvent. The solvent can be water, acidic solution with or without chelating agents or simulated lung fluid. The solution is changed at intervals and analysed to measure the quantity of dissolved radionuclide. The time-dependent retention of non-dissolved Pu on the filter R(t) is fitted by two exponentials to derive values of f r , s r and s s :
The in vitro studies used in this work were published by Eidson and Mewhinney (1983) , Carbaugh and La Bone (2003) , Rateau-Matton et al (2004) .
In vivo studies
The exposure of the animals was carried out by inhalation of an aerosol in most cases or by intratracheal instillation for some experiments with rats and mice. To estimate Pu absorption from animal studies, the same dissolution model was used for all species. However, species-dependent models were applied to represent the deposition and particle transport in the respiratory tract, as well as the gastro-intestinal and systemic biokinetics of the radionuclide. The model predictions of retention in the lung, liver and skeleton (monkey and dog), carcass (rodent) and of the faecal and urinary excretions were fitted to the available observed data by varying the values of f r , s r , s s and of the intake (human) (figure 1).
Human.
The chelating agent diethylene-triamine pentaacetic acid (DTPA) is often used in plutonium decorporation therapy. As DTPA treatment increases the urinary excretion, the published incidental contamination cases were studied when only one intake by inhalation was suspected and no DTPA was administered (Foster 1991 , Ramsden et al 1970 or when DTPA was judged ineffective by the authors (Carbaugh and La Bone 2003) . A human experiment with volunteers was carried out to derive absorption of Pu in human and to compare it with results of animal studies involving the same Pu aerosol (Stradling et al 2002 . The particle deposition, transport and absorption into blood were modelled using the HRTM. The human alimentary tract model (HATM) (ICRP 2006) was applied to derive the faecal excretion. No retention in the walls of the alimentary tract was assumed because it is mainly important for dosimetric applications and because radionuclide retention is generally low and may be ignored in most cases (ICRP 2006) . The values of the fractional absorption into blood from the alimentary tract were taken as f A = 10 −5 for insoluble compounds and f A = 5 × 10 −4 for unknown compounds (ICRP 1994b) . To derive Pu urinary excretion, its behaviour from the uptake into blood up to elimination was modelled according to Leggett (Leggett et al 2005) .
Monkey.
Since human and monkey share a similar physiology and since particle transport rates in the respiratory tract of both species were shown to be close (Bailey et al 1989 , Kreyling et al 1991 , the same behaviour of Pu was assumed in monkey and human. The models used to interpret the monkey data were therefore the HRTM, the HATM, and the Leggett et al (2005) systemic model. The monkey data (baboons, cynomolgus and rhesus monkeys) interpreted in this study are from experiments of Bair et al (1980) , Stanley et al (1980a Stanley et al ( , 1980b Stanley et al ( , 1982 , Métivier et al (1989) , Brooks et al (1992) and Lataillade et al (1995) . 238 Pu dioxide in dog developed by Mewhinney and Diel (1983) were used to interpret systemic organ retention and excretions. The HRTM was applied since particle transport rates in dogs and humans are similar (ICRP 1994a and Kreyling et al 1991) . The experimental data of Bair and McClanahan (1961) , Bair and Willard (1963) , Ballou et al (1972) , McClellan (1972) , Park et al (1972) , Bair et al (1980) , Stanley et al (1980a Stanley et al ( , 1980b Stanley et al ( , 1982 , Dagle et al (1983) , Mewhinney and Diel (1983) , Guilmette et al (1984 Guilmette et al ( , 1987 were interpreted in this work. (2002) developed models of the respiratory tract and Pu systemic behaviour in rats. These were also applied to mouse studies since Bailey et al (1989) suggested that particle transport is similar among rodents. The alveolar deposition was occasionally modified according to the difference of deposition between the different experiments (ICRP 2002) . This study used the data of , Morin et al (1972) , Nénot et al (1972) , Stather and Howden (1975) , Stather et al (1975) , Ballou et al (1977) , Smith et al (1977) , Stradling et al (1978a Stradling et al ( , 1978b , Métivier et al (1980) , Kanapilly and Boecker (1981) , Stanley et al (1982) , Métivier et al (1983) , Stradling et al (1985) , Rhoads et al (1986) , Stradling et al (1987) , Morgan et al (1988) , Stradling et al (1989 Stradling et al ( , 1992 , Moody et al (1993) , Birchall et al (1995) , Lataillade et al (1995) , Stradling et al (1998), Sato et al (1999) , Ramounet et al (2000) , ICRP (2002) 
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Results and discussion
The values of the absorption parameters giving the best fit to the data are shown in figure 2 and table 1 along with some values already provided by the authors of the experiments. When no data provided information about s r , the default value of 100 d −1 was assumed.
Parameter values
Mean and median values of f r , s r and s s were calculated for compounds studied in more than one experiment (table 2) . Median is judged to be the best central estimate of the distributions because it is less sensitive to extreme values. Moreover it may be used together with the geometric standard deviation as parameters of a log-normal distribution approximating the data. No noticeable differences were found between the short-term absorption of 238 PuO 2 (median f r = 1.2×10 −3 ) and 239 PuO 2 (median f r = 1.0×10 −3 ). However, the long-term absorption of 238 PuO 2 (median s s = 1.9 × 10 −3 d −1 ) is faster than for 239 PuO 2 (median s s = 2.8 × 10 −4 d −1 ). This can be explained by the fragmentation of 238 PuO 2 particles due to their higher specific activity (Mewhinney and Diel 1983 , Guilmette et al 1994 , Hickman et al 1995 . The studied chemical forms may be separated in three groups by applying the ICRP Publication 71 criteria (ICRP 1995) : on the one hand, if Pu retention by assuming no particle transport is lower than 13% at 30 d, Type F can be assigned, on the other hand, Type S can be chosen if more than 84% is retained at 180 d; else the absorption can be associated with Type M. From this study, Type S can be assigned to Pu dioxide, MOX, Maralinga soil, Palomares dust, or Pu oxide graphite; Type M to Pu-TBP complex, residues, Pu nitrate, or chloride, Pu-Na alloy, Pu-Mg alloy; Type F to Pu citrate. Moreover, the median and the standard deviation of f r , s r , s s obtained in this work are consistent with the reference values of the ICRP for each category and the illustrative updated default parameter values derived by Bailey et al (2007) (table 3) . They are also broadly consistent with the absorption into blood adopted for the Mayak workers. Khokhryakov et al (2005) .
Most of the in vivo experiments were not designed to obtain accurate values of s r , which would require several measurements on the first day after intake. The determination of s r therefore comes mostly from in vitro experiments because they permit the precise measurement of the dissolved activity at early times. These experiments tend to show ( figure 2, table 1 ) that the default value of 100 d −1 is too high for insoluble compounds such as Pu dioxide and MOX. A value of s r equal to 1 d −1 for Type S compounds is consistent with the available data ( figure 2(b) , table 3) and with Ansoborlo et al (2002) . For Type M Pu compounds, the default value of 10 d −1 could be assigned to s r , in agreement with the provisional updated default value derived by Bailey et al (2007) . In data analysis, assuming that s r default value is equal to 1 d −1 rather than 10 d −1 increases the estimated f r value to keep the same rapid uptake but s s value remains unchanged.
Hypothesis discussion
The most relevant data on absorption from the human respiratory tract obviously come from the follow-up of human contamination cases but these are few and often affected by DTPA treatment. Moreover, they are strongly influenced by individual variability since they usually refer to a single person. On the contrary, rat physiology is quite different from the human one but the individual variability is averaged over the several rats sacrificed at each measurement time. Overall, the results show no real correlation between solubility of Pu and studied animal species. For example, the median s s values for PuO 2 are 9 × 10 −5 for dogs, 1 × 10 −4 for monkeys, 3 × 10 −4 for rats and mice. They are close considering the significant differences in the experimental conditions. This is in agreement with the findings of Stradling et al (2002) which indicated that absorption parameter values in rat and other mammals, and humans, are reasonably independent of species. However, it should be noted that because of the short life of rodents, and the very small value of s s , determination of s s is difficult and will have a large error associated with it. This in turn may inflate the overall uncertainty in s s when applied to humans. In vitro studies can provide a quick and rough evaluation of the solubility of a compound in simulated lung fluid, especially for prospective study of exposure at a workplace and help in the design of monitoring programmes. However, obtaining results that can be applied with reasonable confidence to human exposure is not straightforward (ICRP 2002) . From this study, it appears that in vitro studies give higher long-term absorption and lower short-term absorption than in vivo studies: for MOX, median f r = 5 × 10 −2 and s s = 5 × 10 −5 d −1 for in vitro studies compared to median f r = 1 × 10 −3 and s s = 1 × 10 −4 d −1 for in vivo. It would be interesting to derive central estimate values of f r , s r , s s from this study by weighing differently the data from in vitro, in vivo studies and from human contamination cases. However, the choice of the different weights is not straightforward.
In this work, only dissolution was studied and uptake was considered as instantaneous. However, it is acknowledged that this simplifying assumption may not always be valid, and that a small fraction of dissolved activity can be retained in the lungs for several years . The measured systemic retentions and excretions should not be affected since the fraction of dissolved activity bound to lung tissues appears to be less than 10% . Therefore, the dissolution parameter values derived here would not be noticeably modified by considering a bound fraction of activity. Still the actual presence of a bound fraction would have a large effect on the corresponding lung doses. So, when indication of such bound fraction is available, it can be used together with the dissolution rates to calculate accurate lung doses.
Physically, the dissolution should depend on the particle size through the surface-tovolume ratio (Mercer 1967 , ICRP 1994a . However, Mewhinney and Diel (1983) observed similar absorption rates for aerosols of different sizes (monodispersed aerosols of 0.7, 1.7, 2.7 µm and poly-dispersed aerosol with an AMAD of 1.4 µm) in dogs. Consistently, Guilmette et al (1987) showed that the AMAD had a small influence on the absorption. However, ultrafine particles of a few nanometres behave differently from particles of tens of nanometres and are instantaneously absorbed into blood (Stradling et al 1979) . It can explain the high values of f r reported by Smith et al (1977) and Stradling et al (1978a) who studied the absorption of nanometric particles. On the contrary, Kanapilly and Diel (1980) observed the same dissolution rate constant for ultra-fine and micrometric particles using a different aerosol generator from the above authors. Further study of the absorption of nanometric particles would therefore be of high interest.
The other f r values for PuO 2 and MOX greater than 0.1 were interpreted from Bair and Willard (1963) and Stanley et al (1982) . The latest compared the retention and absorption of the same PuO 2 in rat, dog and monkeys. The short-term absorption was faster in rat lungs than for dogs and monkeys but no clear explanation was provided. The experimental data of Bair and Willard (1963) are expressed as per cent of total Pu intake which includes both the initial lung burden and Pu deposited in the gastro-intestinal tract. This could explain that the lung retention is small just after the exposition leading to a high value of f r .
The simple absorption model used in this study could not be applied to a contamination by a ceramic 238 Pu compound which displays an increasing solubility over time (Guilmette et al 1994 , Hickman et al 1995 , James et al 2003 . The alternative model of absorption to blood in the HRTM (ICRP 1994a) was used by James et al to derive rates for dissolution of particles in initial state s p = 1 × 10 −6 d −1 , for conversion to a transformed state s pt = 1.89 × 10 −3 d −1 and dissolution of transformed particles s t = 2.57 × 10
Committed dose variability
Dose per unit intake (DPUI) was calculated with each determined set of absorption parameters for an inhaled aerosol of pure 239 Pu with an AMAD of 5 µm (figure 3). The calculations were performed with Integrated Modules for Bioassay Analysis (IMBA, Health Protection Agency, UK, Birchall et al 2007) according to the HRTM (ICRP 1994a), GI tract model (ICRP 1979 ) and Pu biokinetic model (ICRP 1993) of ICRP. The DPUI for insoluble compounds and more soluble compounds respectively are close to the published values of Type S and M dose coefficients (ICRP 1994b) . This is consistent with the trend of the estimated solubility rates as well as with the stability of the DPUI which is a weighted average of doses over all radiosensitive tissues. However, estimates of lung dose, particularly when assessed from urinary excretion, are considerably more sensitive to absorption into blood and when a best estimate of lung dose is required, case specific parameter values should be preferred to ICRP reference types.
The uncertainty on the absorption parameters may be propagated to the dose resulting from an inhalation exposure by Monte Carlo calculation. For lack of information, it is often assumed that f r , s r and s s are independent (Bolch et al 2003 , Bess et al 2007 . However, unknown correlations between these parameters may significantly affect the reliability of the results. From the number of sets of values presented here, the actual correlation between f r and s s was studied by the rank correlation Spearman test (figure 4). As a result, f r and s s were found to be significantly correlated (P < 0.01) with a correlation factor of 0.69. This correlation factor may be used to model rank correlation of f r and s s in a Monte Carlo sampling to estimate uncertainty on quantities resulting from an inhalation of Pu, such as the committed dose. On the other hand, no real correlation was found between f r and s r , or s r and s s : it might be because only few values of s r were derived in this study. Alternatively, the discrete sets of three dissolution parameters determined in this study can be sampled to represent the variability in absorption, implicitly taking the correlation between f r , s r and s s into account.
Conclusion
In this study specific values of the absorption parameters for various chemical forms of Pu were determined from in vitro and in vivo experiments and from human contamination cases. These specific values can be applied for a more accurate estimation of intakes and resulting doses.
Nevertheless, it was shown that the use of the current reference absorption types of the ICRP provides a reasonable approximation. Pu dioxide, MOX, oxide graphite, Maralinga soil and Palomares dusts may be considered as insoluble compounds, while Pu nitrate, chloride, Pu-Na alloy, Pu-Mg alloy, Pu-TBP complex and industrial residues may be classified as moderately soluble compounds and citrate as a rapidly soluble compound. Average and median estimates were calculated for f r , s r , and s s for each Pu compound that can be used as better estimates than reference absorption types for a specific chemical form, as recommended by the ICRP (2002) and Bailey et al (2007) , especially for lung dose calculation.
Moreover, this work provides an evaluation of the variability of the absorption parameters which allows uncertainty studies of the evaluation of intake and dose either from bioassay measurement or for prospective dosimetry to be carried out. Finally, a correlation between f r and s s was demonstrated.
This work was focused on the internal exposure of workers. In order to obtain specific absorption values for members of public, it would be useful to extend this study to environmental compounds such as estuarine silt (Morgan et al 1990) . Furthermore, specific absorption parameters should be determined in the future for new Pu chemical forms expected to be present in the fourth generation of nuclear reactor but have not yet been experimentally studied in order to design monitoring programmes for workers and to anticipate dose calculation (Métivier and Guillaumont 2007) .
